Ralley Prentice, Emma Flanagan, Emily K Wright, Peter R Gibson, Sam Rosella, Ourania Rosella, Jakob Begun, Yoon-Kyo An, Ian C Lawrance, Michael A Kamm, Miles Sparrow, Rimma Goldberg, Lani Prideaux, Sara Vogrin, Katerina V Kiburg, Alyson L Ross, Megan Burns, Sally J Bell
BACKGROUND AND AIMS: Vedolizumab and ustekinumab pharmacokinetics in pregnancy and the infant following in-utero exposure remain incompletely defined. We aim to define the antenatal stability of ustekinumab and vedolizumab levels and the time at which infant drug levels become undetectable. METHODS: This multicentre prospective observational cohort study recruited pregnant or preconception women with Inflammatory Bowel Disease receiving vedolizumab or ustekinumab...
March 14, 2024: Clinical Gastroenterology and Hepatology